Background Postoperative ileus (POI) remains a major impediment in patient recovery and leads to longer lengths of stay at the hospital, readmission rates, and hospital costs. Alvimopan, a mu-opioid receptor antagonist, lowers POI incidence following open gastrointestinal surgery, however, little is known about its role on POI prevention among patients undergoing laparoscopic gastrointestinal surgery.
Introduction
Postoperative ileus (POI), defi ned as the transient cessation of coordinated bowel motility aft er surgical intervention, is a common complication following gastrointestinal surgery [1] . Incidence following open versus laparoscopic colectomy has been reported to be 31% and 21%, respectively [2] . POI remains a major impediment in patient recovery and leads to longer lengths of stay, readmission rates, and hospital costs [3, 4] .
Th e etiology of POI is thought to be multifactorial involving sympathetic neural refl exes, local and systemic infl ammatory mediators and changes in many neural and hormonal infl uences [5] . Surgical factors such as longer operations, increased blood loss, increased bowel manipulation and open surgeries also contribute to higher incidences of POI [6, 7] . Laparoscopic surgery is thought to lead to lower incidences of POI due to decreased bowel manipulation, blood loss, and less sympathetic activation. However, while studies have shown that laparoscopic surgery leads to shorter durations of POI of approximately 1 day, POI is still present regardless of the surgical approach [8, 9] .
Another contributing factor to POI is the use of opiates postoperatively for pain control. Opiates exert an analgesic eff ect by acting as opiate receptor agonists within the central nervous system. However, opiates also aff ect peripheral nerve terminals such as those in the enteric nervous system in the gastrointestinal tract. Th is leads to gut dysmotility, decreased fl uid secretion and sphincter dysfunction, which presents as constipation, hard stools, and incomplete evacuation [10] . Alvimopan is an orally administered mu-opioid receptor antagonist that does not cross the blood-brain barrier at clinically relevant doses. It therefore can negate the eff ect of opiates on the bowel while not aff ecting the analgesic properties [11] .
Multiple randomized controlled studies, meta-analyses and a Cochrane review have been performed showing the benefi cial eff ect of alvimopan in lowering the incidence and duration of POI following open gastrointestinal surgery [12] [13] [14] [15] [16] [17] [18] [19] . Following these results, alvimopan was approved by the Food and Drug Administration in 2008 for prevention of POI following major open abdominal surgery in the United States.
While the effi cacy of alvimopan in reducing POI in open gastrointestinal surgery has been proven; no systematic review or meta-analysis to date has reported the eff ect of alvimopan exclusively in laparoscopic gastrointestinal surgery. Th is meta-analysis studies whether the opioid receptor antagonist, alvimopan, is eff ective in reducing POI and readmission rates in patients undergoing laparoscopic gastrointestinal surgery.
Materials and methods

Literature search
A comprehensive literature search was performed from multiple databases in the English language. First, multiple databases, including MEDLINE/PubMed, Cochrane databases, CINAHL, Scopus, and Google Scholar were searched in December, 2014. Search terms included "Alvimopan and abdominal surgery, " "Alvimopan and laparoscopic surgery, " and "Alvimopan and postoperative ileus". If data was incomplete, missing, or required clarifi cation, authors were contacted.
Data extraction
All studies on adult patients that compared the use of alvimopan to placebo with respect to prevention of POI among patients who underwent laparoscopic colorectal surgeries were included. Two reviewers (SM & DLN) independently assessed the trials and extracted the appropriate data included in the analysis. Any disagreements were evaluated and settled by consensus or a third party (MLB).
Study quality assessment
Th e quality of studies was assessed using the Eff ective Public Health Practice Project model [20] . Th is scale assesses study quality as strong, moderate, or weak based upon criteria ratings for selection bias, study design, confounders, blinding, data collection methods, withdrawal and dropout descriptions, intervention integrity, and analysis. Th e quality of the study is based upon how many weak ratings per category (≥2 weak ratings = weak, one weak rating = moderate, and no weak ratings = strong).
Statistical analysis
Meta-analysis for the eff ects of alvimopan compared to placebo with respect to prevention of POI was performed. Th e results were reported using odds ratio (OR) with MantelHaenszel fi xed eff ects model. Heterogeneity was analyzed by calculating the I 2 measure of inconsistency and was considered signifi cant if P<0.10 or I 2 >50%. If heterogeneity was statistically signifi cant, a sensitivity analysis was utilized to examine for heterogeneity when certain studies were excluded from the analysis. Statistical analysis was performed using RevMan 5.1 (Review Manager, Version 5.1, Copenhagen: Th e Nordic Cochrane Centre, Th e Cochrane Collaboration, 2012). Publication bias was assessed by funnel plots. Signifi cance was set at P<0.05.
Results
Study selection
Th e initial literature search identifi ed a total of 38 articles and abstracts (Fig. 1 ). Of the 38 citations found, we excluded 30 duplicate articles, reviews, or assessments that did not exclusively look at laparoscopic surgical technique outcomes with alvimopan use. Among the 8 remaining articles identifi ed, three studies by Wang et al [8] , Absher et al [21] , and Delaney et al [22] were excluded because their primary endpoints did not include the incidence of POI or 30-day readmission. A total of fi ve studies [23] [24] [25] [26] [27] ultimately met our inclusion criteria and were included in the meta-analysis, which compared the eff ectiveness of alvimopan versus placebo in reducing POI and readmission rates in patients undergoing laparoscopic gastrointestinal surgery.
Study details
Th e details of the fi ve included studies are summarized in Table 1 [23] [24] [25] [26] [27] . Th e total number of patients across the fi ve studies was 626. In all studies, alvimopan was administered at a standard dose of 12 mg orally preoperatively and 12 mg b.i.d. postoperatively for maximum of 15 doses [22] . All studies but Abodeely et al [23] [24] [25] [26] [27] mentioned the use of standard perioperative recovery pathways and had similar discharge criteria.
Four of fi ve studies included the incidence of POI as a primary endpoint [23] [24] [25] [26] . All 4 studies had similar defi nitions of POI. Insertion of a nasogastric tube was a primary component of the defi nition of POI in 3 of 4 studies (Abodeely et al, Barletta et al, and Obokhare et al) [23, 24, 26] . Itawa et al [25] defi nition of POI was the least explicit and was defi ned as delay of return of bowel function for 36-48 h postoperatively that could not be attributed to organic cause, usually accompanied by abdominal distention and nausea.
Using the Eff ective Public Health Practice Project model [20] the studies were given an overall rating (Table 1) . All fi ve studies were unblinded prospective or retrospective control trials. Th e studies by Abodeely et al [23] and Whelpley et al [27] were given a rating of strong, given their prospective design, and the remaining 3 retrospective studies [24] [25] [26] were given a rating of moderate.
Prevention of POI
Four of fi ve studies reported rates of POI among patients who underwent laparoscopic colorectal surgery who received alvimopan compared to placebo or no therapy [23] [24] [25] [26] (Fig. 2) . Pooling these 4 studies totaling 531 patients, the rate of POI among patients in the alvimopan group was 3.07% compared to 12.18% in the placebo group. Overall, there was nearly a 75% relative risk reduction in the development of POI when patients were given alvimopan compared to placebo (OR 0.24, 95%CI 0.12-0.51, P=0.02). Th e number needed to treat with alvimopan to prevent one POI episode Figure 1 Algorithm demonstrating the article search POI, post-operative ileus was 11 patients. Th ere was no statistically signifi cant heterogeneity (I 2 <50%).
Length of hospitalization
All 5 included studies evaluated the length of hospitalizations among patients who received alvimopan compared to placebo or no therapy. Four of 5 studies [23, [25] [26] [27] , except the one by Barletta et al, demonstrated a reduction in length of hospitalization between 0.2 and 1.6 days among patients on alvimopan compared to placebo. Despite multiple attempts to pool the studies together to truly defi ne the trend for length of hospitalization, there remains a statistically signifi cant heterogeneity (I 2 >80%).
30-day hospital readmission rate
Four of 5 studies evaluated the frequency of all-cause hospital readmission within the fi rst 30 days from hospital discharge (Fig. 3) [23, [25] [26] [27] . Th ere did not appear to be a diff erence in the frequency of readmission within 30 days of hospital discharge among the alvimopan group compared to placebo (OR 1.15, 95%CI 0.54-2.45). Th ere was no statistically signifi cant heterogeneity (I 2 <50%).
Discussion
Up to 20% of patients undergoing laparoscopic gastrointestinal surgery will develop POI, which leads to increased morbidity, longer lengths of hospital stay, readmission rates, and overall cost of care [2] [3] [4] . Recent data have even reported an increase in length of hospital stay of up to 5 days with an added cost of more than $8000 when POI occurs [2] . Many strategies have been introduced to reduce the incidence of this postoperative complication such as the peripherally acting opioid receptor antagonist alvimopan. Th ough the role of alvimopan in prevention of POI among patients undergoing open abdominal surgery with an overall reduction length of stay. In a recent meta-analysis, Vaughan-Shaw et al demonstrated that there was nearly a 1.5-fold reduction in length of hospitalization among patients undergoing open abdominal surgery [19] . Unfortunately, the role of alvimopan in POI prevention and eff ect on length of hospitalization in laparascopic colorectal surgery remains largely undefi ned.
In this meta-analysis, pooling a total of 531 patients undergoing laparoscopic gastrointestinal surgery, we are the fi rst to demonstrate that patients who were given alvimopan at the standard dose have a 75% relative risk reduction in the development of POI compared to those given placebo. Overall, the number needed to treat to prevent a single episode of POI among patients undergoing laparoscopic surgery was eleven Figure 2 Forest plot of alvimopan compared to placebo for the prevention of post-operative ileus patients. Furthermore, across the indexed studies, we found a reduction in length of stay between 0.2 to 1.6 days. Th ough the length of stay does not appear to be signifi cant, previous studies do suggest that even a small reduction in length of stay can result in a tremendous impact on overall burden of the healthcare system, reduction in cost of care, and improvement of patient's overall quality of life [2, 24] .
Prior studies have shown that POI accounts for more than onethird of readmissions [2, 28] and therefore, a lower incidence of POI should theoretically lead to lower rates of 30 day readmission. Interestingly, while the incidence of POI was decreased in our study, the 30-day all-cause readmission rates did not change in frequency in the patients given alvimopan as compared to those who received placebo or no therapy. Our contradictory fi nding is likely attributed to the fact that the studies included in this metaanalysis did not fully document the primary reason for hospital readmission, which are likely readmissions for postoperative complications other than POI (ie, venous thromboembolism, pneumonia, wound infection etc).
Th ere are several limitations to our meta-analysis. First, the defi nition of POI is not uniform across the indexed studies and the diagnosis was largely based on clinical parameters. Second, while all studies included the endpoint of length of hospital stay, the data could not be pooled from the studies because of signifi cant statistical heterogeneity. Th erefore, the infl uence of alvimopan on length of stay among patients undergoing laparoscopic colorectal surgery remains debated. Future studies will need to defi ne if the introduction of alvimopan is truly cost-savings with regards to marginal reduction in length of stay of 5-38 h. Th ird, the studies included in this metaanalysis do not address which subset of patients undergoing laparascopic surgery may benefi t most from alvimopan
Summary Box
What is already known:
• Postoperative ileus (POI) remains a major impediment in patient recovery and leads to longer lengths of stay at the hospital, readmission rates, and hospital costs • Alvimopan, a mu-opioid receptor antagonist, lowers
POI incidence following open gastrointestinal surgery
What the new fi ndings are:
• Th ere was an over 75% relative risk reduction in POI when patients were given alvimopan compared to patients not receiving alvimopan (OR 0.24, 95%CI 0.12-0.51, P=0.02) • Th e number needed to treat with alvimopan to prevent one POI episode was 11 patients • Th ere was a modest reduction in the length of hospitalization in the alvimopan group, but there was no diff erence in the frequency of the 30-day readmission rate Figure 3 Forest plot evaluating the eff ect of alvimopan on 30-day readmission therapy (i.e., patients on chronic narcotics therapy and elderly) as it may not be cost-eff ective to introduce alvimopan in all subset of patients.
In conclusion, alvimopan appears to be eff ective in reducing POI in patients undergoing laparoscopic gastrointestinal surgery, with a relative risk reduction of over 75%. Additionally, prior studies have shown that alvimopan is well tolerated and is not associated with any adverse events or serious side eff ects [15] [16] [17] . Th erefore, the standard dose of alvimopan should be considered in patients undergoing laparoscopic gastrointestinal surgery, particularly in patients at high risk for POI, including male gender, preoperative use of narcotics, older age, elevated body mass index, low preoperative albumin, history of respiratory comorbidity and peripheral vascular disease, and operation lasting ≥3 h [29, 30] . Future studies will need to address the cost-eff ectiveness of empiric introduction of alvimopan among all patients undergoing laparoscopic gastrointestinal surgery versus selective administration only to high-risk patients with regards to POI prevention, length of hospitalization, hospital readmission, and quality of life.
